Top Pharmaceutical Companies in Mumbai (39)
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for...
Pfizer's Top Stability & Growth Strengths
Product Line Growth: Launched and acquired products are expanding at a double‑digit pace (e.g., +18% operational in Q2 2026), led by assets such as Eliquis, Padcev, the Vyndaqel family, and Lorbrena. Excluding Comirnaty and Paxlovid, revenue grew mid‑single digits, signaling healthy momentum in the core portfolio.
Cost & Operational Efficiency: A multi‑year cost realignment targets about $5.7B in net savings by end‑2026, with a further $2.5B in productivity gains planned for 2027–2029. These actions have supported improved adjusted earnings even as headline revenue normalizes post‑COVID.
Innovation-Driven Growth: A robust late‑stage pipeline and oncology expansion following the Seagen acquisition underpin future growth, with numerous pivotal study starts in 2025–2026. Company commentary highlights oncology and obesity programs as key catalysts into the back half of the decade.
Medikabazaar is a leading healthcare solutions provider, revolutionizing the way medical supplies are procured. With our cutting-edge e-commerce platform, we empower healthcare institutions, clinics, and individual practitioners to streamline their purchasing processes, saving time and resources. At Medikabazaar, we understand the unique challenges faced by the healthcare industry, and we are committed to delivering innovative solutions. Our extensive catalog offers...
The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions...
A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a...
Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. Sun...
We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions....
Indegene's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyst assessments place the company in leadership cohorts for life sciences commercial AI/analytics and digital services for commercial operations, indicating defensible positioning in its specialization. The company is also described as a best-fit provider for digital commercialization, omnichannel activation, content operations at scale, and AI-driven commercial analytics, reinforcing category leadership within that lane.
Strong Revenue Growth: Revenue shows clear acceleration into FY26, including a strong year-over-year increase in the latest reported quarter and a positive exit rate from prior quarters as deal wins converted. Full-year FY25 results also show year-over-year growth alongside continued profitability, supporting an upward growth trajectory.
Product Line Growth: Capability expansion is evidenced by recent acquisitions intended to deepen data-driven omnichannel, media offerings, and consulting/transformation coverage, broadening the commercialization toolkit. Ongoing scaling post-IPO is also framed as broadening capabilities beyond prior scope within its core focus areas.
We’re an innovative and forward-thinking Commercial Pharma analytics startup based in the UK. Since 2014 we’ve been focusing our efforts on providing cutting edge input to pharmaceutical organisations throughout Europe and North America. By combining years of experience in healthcare, pharmaceutical and data , we provide a powerful tool for acquiring real actionable insights to Commercial strategy, Formulary status, Salesforce...
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how...
GSK's Top Stability & Growth Strengths
Strong Market Position & Advantage: GSK is positioned as a top-tier global biopharmaceutical company by revenue while showing category leadership in vaccines and HIV, anchored by franchises such as Shingrix and ViiV’s portfolio. Its consistent top-10/12 standing and segment leadership in vaccines, respiratory, and HIV support a stable competitive footing.
Resilient & Sustainable Growth: Revenue and earnings momentum are supported by broad-based growth across Specialty Medicines and continued contributions from Vaccines, alongside reaffirmed multi-year sales ambitions. Guidance for continued turnover and profit expansion indicates an expectation of ongoing, steadier growth rather than a one-off spike.
Healthy Cash Flow: Operating cash generation is described as strong and is being used to fund R&D investment and shareholder returns such as dividends and buybacks. This cash profile supports resilience through investment cycles and potential volatility in specific product areas.
A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables...
Ajanta Pharma Limited (APL) is a pharmaceutical company headquartered in Mumbai, India. It has strong presence in Branded Generic business in India & Emerging markets; and Generic business in USA. In India, company operates in selected therapeutic areas of Cardiology, Dermatology, Ophthalmology and Pain management. It's brands hold leadership positions in sub-therapeutic areas they are present in.
Panacea Biotec is a research-based health management company involved in research, manufacturing and marketing of high-quality, affordable pharmaceutical, vaccines and herbal products. The product portfolio includes highly innovative prescription products in important therapeutic areas like pain management, diabetes, cardiovascular, renal disease management, osteoporosis, gastro-intestinal care products and vaccines. Panacea Biotec is committed towards disease prevention by introducing Innovative Vaccines that...
Piramal Group is an Indian multinational conglomerate with a presence across healthcare, life sciences, drug discovery, financial services, alternative investment, and real estate.
Wockhardt is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Specialty Hospitals. Wockhardt is a true Indian Multi-National Company with a multi-ethnic workforce of 3000 Wockhardt Associates from 21 different nationalities globally. It...
Lupin is a global pharmaceutical company offering Branded and Generic Formulations, Biosimilars and Active Pharmaceutical Ingredients (APIs). Founded over 50 years ago, Lupin today is a significant player in the US, India and Japan and additionally in other counties within APAC, EMEA and LATAM. It holds a global leadership position in Anti-TB and Cephalosporin segments. Today Lupin is focused on...
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Novartis's Top Stability & Growth Strengths
Strong Revenue Growth: Novartis shows multi-year sales expansion, with full-year results indicating continued top-line growth driven by priority brands across several therapeutic areas.
Profitability: Margins and operating income are described as strengthening, with core operating margin reaching about 40% alongside year-over-year core operating income growth.
Innovation-Driven Growth: Growth is supported by scaling priority brands and a deep pipeline with multiple high-value assets, alongside business development to add late- and mid-stage programs.
Apotex Inc. is a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines for patients around the world. Apotex employs almost 8,000 people worldwide in manufacturing, R&D, and commercial operations. Apotex Inc. exports to more than 100 countries and territories and operates in more than 45 countries, with a significant presence in Canada, the US, Mexico, and India. Through...
At Endo, our far-reaching vision is simple: to help everyone we serve live their best life. As a specialty pharmaceutical company, we’re motivated by a strong sense of purpose to find better ways to meet unique medical needs. Our global team of passionate employees understands the importance of their work. We’re dedicated to supporting one another as we connect with communities...
Endo's Top Stability & Growth Strengths
Strong Market Position & Advantage: Xiaflex is the only FDA‑approved nonsurgical therapy for Peyronie’s disease and an FDA‑approved option for Dupuytren’s contracture, giving the franchise clear category leadership within this narrow segment. Marketing continued into 2025 with national campaigns reinforcing this positioning.
Product Line Growth: Xiaflex posted record 2024 sales and grew again in Q1 2025, with the Branded segment up in the quarter. New sterile injectable launches (e.g., ADRENALIN ready‑to‑use premixed bags) add to near‑term product momentum.
Future-Ready Strategy: The April 2024 emergence from Chapter 11 reduced debt and removed significant litigation overhang, enabling renewed focus on branded growth and selected sterile injectables. Management reaffirmed 2025 guidance implying stabilization with potential slight growth and announced portfolio‑reshaping moves including a combination with Mallinckrodt and an international divestiture.
Titan is a speciality pharmaceutical & generic formulation company engaged in developing & manufacturing Sustained & Modified Release Pellets, DC Granules, & Taste Masked Granules.
Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the...
Profound Change Requires Boldness. Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the...
Johnson & Johnson's Top Stability & Growth Strengths
Strong Revenue Growth: Companywide sales are described as increasing year over year, with momentum exiting 2025 and guidance calling for continued expansion into 2026.
Innovation-Driven Growth: Growth is attributed to innovative medicines and new product submissions, with oncology and immunology performance highlighted as key contributors.
Diversified Revenue Streams: The business is positioned around two large segments—Innovative Medicine and MedTech—creating a broader platform that helps offset declines in specific products.
